TBPH
Theravance Biopharma Inc.
Company Overview
| Mkt Cap | $835.73M | Price | $16.56 |
| Volume | 422.64K | Change | +0.00% |
| P/E Ratio | -14.8 | Open | $16.22 |
| Revenue | $64.4M | Prev Close | $16.56 |
| Net Income | $-56.4M | 52W Range | $7.90 - $21.03 |
| Div Yield | N/A | Target | $16.17 |
| Overall | 49 | Value | 80 |
| Quality | -- | Technical | 18 |
No chart data available
About Theravance Biopharma Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Latest News
Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH) and Phreesia (PHR)
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
Wall Street Analysts Are Bullish on Top Healthcare Picks
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TBPH | $16.56 | 0% | 422.64K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Theravance Biopharma Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW